-
DAVIDsTEA Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
02 May 2024 11:00 GMT
… to $12.0 million
Q4 Fiscal 2023
Sales of $ … fulfillment challenges experienced in the fourth quarter of fiscal 2022. E- … of payroll, ongoing technology expenditures and other operating costs. Our … 4,000 grocery stores and pharmacies, and 18 company-owned …
-
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
02 May 2024 12:34 GMT
… growth compared to Q4 2023 and 40% … diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) … investigations; and unexpected expenditures; as well as … authority approval.
ALNYLAM PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE …
-
Sensex Today Live Updates : Sensex up 230pts, Nifty at 22,640; Auto, FMCG, Pharma, O&G gain, Bank index under pressure
02 May 2024 06:38 GMT
… projections for FY25 and capital expenditure forecasts for the current … indices like FMCG, Auto, Pharma and Healthcare leading the gains … ₹168 crore for the fourth quarter that ended in March 2024 … fourth quarter of this fiscal year, up from ₹195.2 crore in Q4 …
-
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights
30 Apr 2024 11:00 GMT
… 2.2 million for Q4-2022
Q4-2023 Net loss of … ” or “LSL Pharma”), a Canadian integrated pharmaceutical company, today reported … $3 million for Q4-2022.
Q4-2023 Business Highlights
October … for working capital, capital expenditures, and for general corporate …
-
West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Call Transcript
30 Apr 2024 13:38 GMT
… Transcript April 25, 2024
West Pharmaceutical Services, Inc. beats earnings … by. Welcome to West Pharmaceutical Services First Quarter 2024 … more typical order patterns in Q4. Therefore, after a … and/or capital expenditures offset by cash from operations …
-
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2023 Q4 AND FULL YEAR FINANCIAL RESULTS
29 Apr 2024 20:30 GMT
… s 2023 full year and fourth quarter, ending December 31, 2023 … system constituents, such as independent pharmacies. On November 21, 2023 … Adjusted EBITDA for Q4 2023 versus Q4 2022 was primarily … Group reports contributions and expenditures on a gross basis on …
-
Accuray Reports Fiscal 2024 Third Quarter Financial Results
02 May 2024 14:18 GMT
MADISON, Wis., May 1, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024.
Third Quarter Fiscal 2024 Summary
Net revenue of $101.1 million decreased 14 …
-
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
02 May 2024 20:34 GMT
… data readouts in the fourth quarter that could serve as … is expected in the fourth quarter of 2024.
Chronic Hepatitis … charges are primarily non-cash expenditures, related to the closing … Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter …
-
WW International, Inc. Announces First Quarter 2024 Results
02 May 2024 20:01 GMT
End of Period Subscribers of 4.0 million, including 91 thousand End of Period Clinical Subscribers
Revenues of $206.5 million
Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross …
-
The Chemours Company (NYSE:CC) Q1 2024 Earnings Call Transcript
02 May 2024 18:06 GMT
… maintenance outage during the fourth quarter of 2023, which remains … of $290 million. Capital expenditures were $102 million in … agents and propellants, including pharmaceutical grades. Approximately 80% of … be completed during the fourth quarter of this year, …